Published in Br J Cancer on November 01, 1994
Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies. Radiology (2013) 1.39
Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am J Pathol (1998) 1.10
Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma. Oncol Lett (2011) 0.75
Autocrine secretion and malignant transformation of cells. N Engl J Med (1980) 7.49
Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A (1983) 5.00
Transmembrane TGF-alpha precursors activate EGF/TGF-alpha receptors. Cell (1989) 2.65
Transforming growth factor alpha. Cell (1988) 2.56
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res (1993) 2.14
Transforming growth factor-alpha. A model for membrane-anchored growth factors. J Biol Chem (1990) 2.00
The many faces of epidermal growth factor repeats. New Biol (1990) 1.94
Intercellular communication and cell-cell adhesion. Science (1992) 1.83
Asbestos-associated chromosomal changes in human mesothelial cells. Proc Natl Acad Sci U S A (1985) 1.60
Cell-cell adhesion mediated by binding of membrane-anchored transforming growth factor alpha to epidermal growth factor receptors promotes cell proliferation. Proc Natl Acad Sci U S A (1990) 1.40
Asbestos fibers and silica particles stimulate rat alveolar macrophages to release tumor necrosis factor. Autoregulatory role of leukotriene B4. Am Rev Respir Dis (1989) 1.35
Autocrine secretion--10 years later. Ann Intern Med (1992) 1.31
Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res (1987) 1.30
p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res (1992) 1.20
Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. Proc Natl Acad Sci U S A (1993) 1.20
Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer (1992) 1.20
Multiple mechanisms for the carcinogenic effects of asbestos and other mineral fibers. Environ Health Perspect (1989) 1.02
Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors. Oncogene (1988) 0.97
Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene (1991) 0.96
Anti-sense transforming growth factor alpha oligonucleotides inhibit autocrine stimulated proliferation of a colon carcinoma cell line. Mol Biol Cell (1992) 0.95
Normal human mesothelial cells and fibroblasts transfected with the EJras oncogene become EGF-independent, but are not malignantly transformed. Oncogene Res (1988) 0.95
Loss of growth responsiveness to epidermal growth factor and enhanced production of alpha-transforming growth factors in ras-transformed mouse mammary epithelial cells. J Cell Physiol (1987) 0.93
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer (1990) 0.93
Growth factors: regulation of normal and neoplastic growth. J Pathol (1993) 0.90
Tumorigenicity of human mesothelial cell line transfected with EJ-ras oncogene. J Natl Cancer Inst (1989) 0.89
Role of transforming growth factor alpha (TGF-alpha) in the transformation of ras-transfected rat intestinal epithelial cells. Oncogene (1993) 0.89
Interferon-induced enhancement of transforming growth factor-alpha expression in a human breast cancer cell line. Proc Soc Exp Biol Med (1993) 0.87
Anchorage-independent growth of normal human mesothelial cells: a sensitive bioassay for EGF which discloses the absence of this factor in fetal calf serum. In Vitro Cell Dev Biol (1985) 0.87
Human epidemiology: a review of fiber type and characteristics in the development of malignant and nonmalignant disease. Environ Health Perspect (1990) 0.87
An autocrine mitogenic activity produced by a pleural human mesothelioma cell line. Int J Cancer (1992) 0.87
Differential responses to growth factors by normal human mesothelial cultures from individual donors. J Cell Physiol (1989) 0.84
Potential role of two novel elastase-like enzymes in processing pro-transforming growth factor-alpha. Biochemistry (1993) 0.83
Immunohistochemical distribution patterns of epidermal growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch A Pathol Anat Histopathol (1991) 0.83
Tumorigenic conversion of human mesothelial cells as a consequence of platelet-derived growth factor-A chain overexpression. Am J Respir Cell Mol Biol (1993) 0.81
Biotinylated epidermal growth factor: a useful tool for the histochemical analysis of specific binding sites. Histochem J (1990) 0.81
Establishment of human malignant mesothelioma cell lines. Int J Cancer (1989) 0.80
Bidirectional modulation of TNF-alpha production by alveolar macrophages in asbestos-induced pulmonary fibrosis. J Leukoc Biol (1993) 0.80
Biology of small cell lung cancer: an overview. Eur Respir J (1990) 0.80
Recombinant human granulocyte-macrophage colony-stimulating factor induces secretion of autoinhibitory monokines by U-937 cells. Eur J Immunol (1988) 0.79
Growth control in a human colon carcinoma cell line mediated by cell-associated transforming growth factor-alpha (TGF alpha). Exp Cell Res (1993) 0.78
Transforming growth factor-alpha and its role in neoplastic progression. Cancer Treat Res (1992) 0.78
Mitogenic effects of a mesothelial cell growth factor: evidence for a potential autocrine regulation of normal and malignant mesothelial cell proliferation. Int J Exp Pathol (1992) 0.77
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res (2000) 2.32
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol (2007) 1.85
Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst (1997) 1.78
Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. J Clin Oncol (1985) 1.64
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol (1997) 1.61
CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res (1992) 1.57
Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11. Br J Cancer (1989) 1.57
Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol (1989) 1.51
Tumor-associated membrane sialoglycoprotein on human small cell lung carcinoma identified by the IgG2a monoclonal antibody SWA20. Cancer Res (1988) 1.44
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol (2001) 1.35
Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer (1992) 1.20
Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen. Br J Cancer (1990) 1.17
Developmental regulation of micro-injected histone genes in sea urchin embryos. Dev Biol (1988) 1.17
Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett (2007) 1.17
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol (2004) 1.17
Characterization of an epithelial and a tumor-associated human small cell lung carcinoma glycoprotein antigen. Cancer Res (1987) 1.15
Murine monoclonal antibody LAM2 defines cell membrane determinant with preferential expression on human lung small-cell carcinoma and squamous-cell carcinomas. Int J Cancer (1985) 1.14
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Eur Respir J (2011) 1.14
Expression of the small cell carcinoma antigens of cluster-5 and cluster-5A in primary lung tumours. Br J Cancer (1989) 1.13
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol (2005) 1.10
Cytotoxic murine monoclonal antibody LAM8 with specificity for human small cell carcinoma of the lung. Cancer Res (1986) 1.09
Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer (1998) 1.08
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (2000) 0.97
The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies. Br J Cancer (1994) 0.95
Imaging and therapy of small cell carcinoma xenografts using 131I-labeled monoclonal antibody SWA11. Cancer Res (1990) 0.92
A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res (2000) 0.92
Monoclonal anti-idiotypic antibody mimicking a tumor-associated sialoglycoprotein antigen induces humoral immune response against human small-cell lung carcinoma. Int J Cancer (1989) 0.91
Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. Int J Cancer (2000) 0.91
Cytoskeleton-associated proteins: their role as cellular integrators in the neoplastic process. Crit Rev Oncol Hematol (1985) 0.90
Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer. Br J Cancer Suppl (1991) 0.90
T-cell derived cytokines co-stimulate proliferation of CD40-activated germinal centre as well as follicular lymphoma cells. Hematol Oncol (1997) 0.89
Selective immunotherapy of small cell cancer xenografts using 131I-labelled SWA11 antibody. Br J Cancer (1991) 0.88
Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. Eur J Cancer Clin Oncol (1984) 0.87
An autocrine mitogenic activity produced by a pleural human mesothelioma cell line. Int J Cancer (1992) 0.87
Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line. Biochem Biophys Res Commun (1996) 0.87
Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells. Int J Cancer (2000) 0.86
The small cell lung cancer antigen cluster-4 and the leukocyte antigen CD24 are allelic isoforms of the same gene (CD24) on chromosome band 6q21. Cytogenet Cell Genet (1995) 0.86
Antibodies to the protein core of the small cell lung cancer workshop antigen cluster-w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucine-alanine-proline. Clin Exp Immunol (1993) 0.85
Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res (2001) 0.85
Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung. J Clin Invest (1985) 0.85
Persistent polyclonal B-cell lymphocytosis is an expansion of functional IgD(+)CD27(+) memory B cells. Br J Haematol (2001) 0.85
Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst (2001) 0.85
DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells. J Neurooncol (2005) 0.85
Incidence of childhood Type I diabetes mellitus is increasing at all ages in Germany. Diabetologia (2002) 0.85
Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann Oncol (2005) 0.84
Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. Br J Cancer (1990) 0.84
A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer. Cancer Immunol Immunother (1997) 0.83
Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines. Br J Cancer (1992) 0.83
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia. Ann Oncol (2005) 0.83
Expression of alternatively spliced forms of the CD44 extracellular-matrix receptor on human lung carcinomas. Int J Cancer Suppl (1994) 0.83
The 5'-flanking region of human CD24 gene has cell-type-specific promoter activity in small-cell lung cancer. Int J Cancer (1998) 0.83
Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. Br J Cancer (1991) 0.82
Monoclonal antibody SEN7 recognizes a new epitope on the neural cell adhesion molecule present on small cell lung cancer but not on lymphocytes. Cancer Res (1993) 0.81
Lung tumor cells: a multivariate approach to cell classification using two-dimensional protein pattern. Electrophoresis (1995) 0.81
The drop height determines neuromuscular adaptations and changes in jump performance in stretch-shortening cycle training. Scand J Med Sci Sports (2011) 0.81
Novel approaches to the treatment of small-cell lung cancer. Cell Mol Life Sci (1999) 0.80
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer (1999) 0.80
Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie (2003) 0.80
Biodistribution and tumour localisation of 131I SWA11 recognising the cluster w4 antigen in patients with small cell lung cancer. Br J Cancer (1993) 0.80
Action of a CD24-specific deglycosylated ricin-A-chain immunotoxin in conventional and novel models of small-cell-lung-cancer xenograft. Int J Cancer (1993) 0.80
Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer. Br J Cancer (1992) 0.80
Selective cytotoxicity of the SM1 monoclonal antibody towards small cell carcinoma of the lung. Cancer Res (1985) 0.79
Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study. Oncology (2000) 0.79
ME1-antibody labelling of primary bronchogenic tumours and extrapulmonary malignancies. Lung Cancer (1994) 0.79
Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice. Int J Cancer (1996) 0.78
Monoclonal antibodies defining the cluster-5A small cell lung carcinoma antigen. Br J Cancer Suppl (1991) 0.78
Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells. Cancer Immunol Immunother (1996) 0.78
Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer. Cancer Immunol Immunother (1992) 0.78
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease. Ann Oncol (2005) 0.78
Surgical resection of residual tumor after chemotherapy in non-seminomatous testicular cancer. Eur J Cancer Clin Oncol (1982) 0.78
Reduction of systemic fungal infections in patients with hematological malignancies, neutropenia, and prolonged fever by early amphotericin B therapy. Klin Wochenschr (1988) 0.78
ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. Am J Pathol (1990) 0.78
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). Ann Oncol (2005) 0.78
Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells. Blood (1996) 0.77
Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule. Clin Exp Immunol (1992) 0.77
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma. Br J Cancer (1995) 0.77
Selective cytotoxicity of murine monoclonal antibody LAM2 against human small-cell carcinoma in the presence of human complement: possible use for in vitro elimination of tumor cells from bone marrow. Int J Cancer (1985) 0.77
Modulation of neuroendocrine surface antigens in oncogene-activated small cell lung cancer lines. Br J Cancer Suppl (1991) 0.77
Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors. Ann Oncol (1992) 0.77
Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer. Int J Cancer (1993) 0.77
Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma. Ann Oncol (1993) 0.76
Primary non-small cell lung cancer response upon treatment with denosumab. Lung Cancer (2013) 0.76
[Systemic mycoses in hematologic neoplasms]. Schweiz Med Wochenschr (1983) 0.76
Radiation studies on B cell differentiation marker CD24/SCLC Cluster-4 antigen expressing and non-expressing lung cancer cell lines and mouse fibroblasts. Int J Radiat Biol (1995) 0.76
Polyclonal anti-idiotypic antibodies mimicking the small cell lung carcinoma antigen cluster-5A interact with a panel of antibodies and induce specific immune response in animals. Br J Cancer Suppl (1991) 0.75
Reversible pulmonary hypertension secondary to mitral valvular disease as an indication for extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth (1991) 0.75
Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer. Br J Cancer (1994) 0.75
Comment on "A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer", by C. M. Rudin et al. (Ann Oncol 2002; 13: 539-545). Ann Oncol (2003) 0.75
A comparison of 67Cu- and 131I-labelled forms of monoclonal antibodies SEN7 and SWA20 directed against small-cell lung cancer. Int J Cancer Suppl (1994) 0.75
In vitro effect of suramin on lung tumour cells. Eur J Cancer (1993) 0.75
Tumor-antigen-specific humoral immune response of animals to anti-idiotypic antibodies and comparative serological analysis of patients with small-cell lung carcinoma. Int J Cancer (1992) 0.75
Statistical analysis of data from the Third International IALSC Workshop on Lung Tumor and Differentiation Antigens. Int J Cancer Suppl (1994) 0.75
Placebo controlled phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy. Ann Oncol (1990) 0.75
Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma. Br J Haematol (1991) 0.75
[5 years of dosage intensification and autologous bone marrow or peripheral stem cell transfusion in malignant lymphoma with a high risk of recurrence]. Schweiz Med Wochenschr (1993) 0.75
[Creativity in Wieck's syndrome. Designing and choice of color in subsiding poisoning with hypnotics]. Med Welt (1971) 0.75